Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma.
暂无分享,去创建一个
M. Milowsky | D. Bajorin | C. Sternberg | J. Rosenberg | M. Shi | W. Stadler | M. Squires | D. Quinn | L. Cerbone | S. Jagdev | I. Durán | C. Sweeney | F. Millard | C. Dittrich | P. Sen | Melissa Lochheed